The use of clinical biomarkers has grown exponentially since they were first employed in the 1970s. The sequencing of the human genome and development of omics technologies have significantly accelerated the development and adoption of biomarkers in drug discovery and development, as well as clinical decision making.

Biomarkers for precision medicine in oncology has probably seen the greatest benefit from this technological innovation with new developments continuing to push boundaries. Biomarkers in other disease areas are now following behind the precedent set in oncology. These are facing different challenges but have significant potential to facilitate better treatment options for patients.

This session will discuss how appropriate, well validated, biomarkers will drive a reduction in drug attrition in all therapeutic areas over the next few decades.

**Plenary Keynote Speaker**

Fiona Marshall (MSD)

**Confirmed Speakers**

Peter O’Toole (University of York)
Gregory Hamm (AstraZeneca)
Sally Price (Medicines Discovery Catapult)
Ian Pike (Ian Pike Consulting)
Andrea Malaspina (Queen Mary University)

**Call for Posters**

For an opportunity to present your research in one of our poster spotlight sessions, submit your abstract by **8TH October 2019**. The general poster abstract submission deadline is **27TH October 2019**.

**Sponsorship & Exhibition**

For further information on sponsorship & exhibition opportunities, including multi-show discounts, please e-mail ELRIG General Manager: Sanj Kumar sanj.kumar@elrig.org

Follow us for all the latest information on ELRIG events and news.

Register for Drug Discovery 2019 FREE now: **www.elrig.org**